Tweet by Dr. John Cush

Professor van Vollenhoven has compiled a state-of-the-art review on lupus treatment advances – current and future. SLE management is entering an unprecedented phase.

Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) often overlap. While there have been some therapeutic advances, significant needs remain around diagnosis and monitoring, with a gap around definitions and biomarkers for refractory disease or specific subsets. EULAR – The…

Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants. But no operational definition is widely accepted, limiting trial eligibility, outcome benchmarking, and…